OTCMKTS:NVZMY Novozymes A/S Q2 2026 Earnings Results & Report $65.26 +0.97 (+1.51%) As of 10/9/2026 03:59 PM Eastern Novozymes A/S missed analyst earnings expectations but beat on revenue in its Q2 2026 results, released August 20, 2026. The company reported EPS of $0.44 versus the $0.60 consensus estimate, while revenue of $1.30 billion topped the $1.27 billion estimate by $29.01 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 20, 2026TimeBefore Market Opens Novozymes A/S EPS ResultsActual EPS$0.44Consensus EPS $0.60Beat/MissMissed by -$0.16One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersNovozymes A/S Revenue ResultsActual Revenue$1.30 billionExpected Revenue$1.27 billionBeat/MissBeat by +$29.01 millionYoY Revenue GrowthN/AUpcoming EarningsNovozymes A/S' next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Novozymes A/S Q2 2026 Earnings FAQ Did Novozymes A/S beat earnings estimates for Q2 2026? Novozymes A/S (OTCMKTS:NVZMY) reported earnings of $0.44 per share for Q2 2026, missing the consensus estimate of $0.60. The report was announced on Thursday, August 20, 2026. What was Novozymes A/S' revenue for Q2 2026? Novozymes A/S reported revenue of $1.30 billion for Q2 2026, against a consensus estimate of $1.27 billion. When is Novozymes A/S' next earnings date? Novozymes A/S' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Novozymes A/S on the company's earnings history page. Novozymes A/S Earnings HeadlinesNovozymes A/S (OTCMKTS:NVZMY) vs. Neo Performance Materials (OTCMKTS:NOPMF) Head to Head ReviewOctober 6, 2026 | americanbankingnews.comNovozymes A/S (NVZMY) Q2 2026 Earnings Call TranscriptAugust 20, 2026 | seekingalpha.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 11 at 1:00 AM | Stansberry Research (Ad)Novonesis (Novozymes) B ADR NVZMYAugust 5, 2026 | morningstar.comMNovozymes AS DRC (NVZMY)June 24, 2026 | investing.comA Look At Novozymes (CPSE:NSIS B) Valuation After Recent Share Price WeaknessMay 14, 2026 | uk.finance.yahoo.comSee More Novozymes A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Novozymes A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novozymes A/S and other key companies, straight to your email. Email Address About Novozymes A/SNovozymes A/S (OTCMKTS:NVZMY) was a Danish biotechnology company specializing in biological solutions based on enzymes, microorganisms and related technologies. Its products were designed to help businesses improve manufacturing efficiency, reduce resource use and develop more sustainable alternatives to conventional chemical processes. The company supplied enzyme and microbial products for a range of industries, including household care, food and beverages, agriculture, animal health, bioenergy and industrial manufacturing. Applications included laundry and cleaning products, baking and brewing, starch processing, animal feed, crop-related solutions and the production of biofuels and other biobased materials. Novozymes was established as an independent company in 2000 after being separated from Novo Nordisk and served customers across global markets through research, production and commercial operations in multiple regions. In January 2024, Novozymes combined with Chr. Hansen, another Danish bioscience company, to form Novonesis. Ester Baiget served as Novozymes’ president and chief executive officer before and during the combination process.View Novozymes A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
